Crick — Clinical Intelligence Platform

Early research (Phase 1)Study completedNCT01014936

What this trial is testing

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Who this might be right for

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

EMD Serono 149

Results for “Solid Tumors Refractory To Standard Therapy”

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Stem Cell Transplantation for Metastatic Solid Tumors

HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A24 or A02-positive Advanced Solid Tumors

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Results for “Solid Tumors Refractory To Standard Therapy”

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Stem Cell Transplantation for Metastatic Solid Tumors

HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A24 or A02-positive Advanced Solid Tumors